Industry Analysis & Industry Trends
With healthcare reform allowing more individuals to gain prescription coverage, brand-name pharmaceutical and medicine manufacturers will experience a boost in demand. Rising production of branded follow-on biologic drugs will be important in offsetting the effects of widespread patent expirations, though a major increase in taxes and discounts to fill the Medicare coverage gap threatens profit in the industry... purchase to read more
Industry Report - Industry Key Buyers Chapter
This industry has a low level of market share concentration, with the four largest firms accounting for less than 37.0% of industry revenue. Consolidation in this industry has increased in recent years. The biggest headlines involved the Pfizer-Wyeth, Merck-Schering-Plough and Roche-Genentech mergers in 2009. Consolidation has been primarily driven by escalating costs of research and development, shorter exclusivity times and the need for global marketing power. Mergers and acquisitions have also been spurred by growing competition from generic pharmaceutical manufacturers.
Despite steady industry consolidation, market share concentration has remained relatively low. Many major players suffered falling sales over the past two years due to strong competition from generic drugs... purchase to read more